Emisphere Tech (EMIS) 0.3800 $EMIS
Emisphere enters into USD20m debt financing to introduce oral Eligen B12 in the US market
M2 - Thu Aug 21, 7:31AM CDT
Pharmaceutical company Emisphere Technologies (OTC BB:EMIS) reported on Wednesday the execution of new loan facility agreement to finance the upcoming launch of its first commercial prescription product oral Eligen B12 in the US for B12 deficient individuals.
Emisphere Announces $20 Million Debt Financing to Launch Oral Eligen(R) B12
GlobeNewswire - Wed Aug 20, 8:29AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company"
today announced that it has reached agreement with MHR Fund Management LLC, and certain of its affiliated funds ("MHR" , to finance the upcoming launch of the Company's first commercial prescription product, oral Eligen B12 in the United States through a new loan facility, and to amend the terms of the Company's existing obligations under various promissory notes previously issued to MHR to extend the maturity dates of such promissory notes.
Competitor Analysis: GLP-1 Receptor Agonists Development Pipeline Report 2014
M2 - Tue Aug 19, 9:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7d4zkt/competitor) has announced the addition of the "Competitor Analysis: GLP-1 Receptor Agonists" report to their offering. The Competitive Intelligence Report Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists as of August 2014 provides a competitor analysis in the development pipeline of novel GLP-1 analogs and GLP-1 receptor agonists and co-agonists for treatment of diabetes and obesity. In the year 2013, the marketed daily and weekly GLP-1 agonists achieved combined sales of US$ 3,231 mln representing 6.3% of the total diabetes care market. The leading GLP-1 analog Victoza held 69% of the GLP-1 market and is further expanding its predominance in the first half of 2014 with a 72% share of the GLP-1 market which grew to 6.9% of the total diabetes care market. The increasingly attractive GLP-1 market provides an opportunity of application of new technologies to prolong the half-life of GLP-1 analogs as well as finding co-agonists of GLP-1 receptor with additional receptors, such as insulin, glucagon, GIP, gastrin or GLP-1. In addition, expansion of indications for GLP-1 analogs will contribute to further expand the GLP-1 market. The report provides a compilation of current active projects in research and development of novel GLP-1 analogs and GLP-1 receptor agonists as well as co-agonists. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage - Additional comments with a hyperlink leading to the source of information. Key Topics Covered: 1. Selective GLP-1 Analogs for Metabolic Diseases - 2013 Sales of GLP-1 Analogs - Short-Acting Injectable GLP-1 Analogs - Long-Acting Injectable GLP-1 Analogs - Very Long-Acting Injectable GLP-1 Analogs - Oral Peptide-Based GLP-1 Analogs - Other Non-Injectable Peptide-Based GLP-1 Analogs - Oral Small Molecule GLP-1 Receptor Agonists 2. Selective GLP-1 Analogs for Non-Metabolic Diseases 3. Dual Target GLP-1 Analogs - GLP-1 and Insulin - GLP-1 and Glucagon - GLP-1 and GIP - GLP-1 and Gastrin/CCKB - GLP-1 and GLP-2 4. Corporate GLP-1 Receptor Agonist R&D Pipelines Companies Mentioned - Addex Pharmaceuticals - Amylin Pharmaceuticals - Arisaph Pharmaceuticals - Arisgen - Ascendis Pharma (Complex Biosystems) - Bio-ker - Biocompatibles International - ConjuChem - Dong-A Pharmaceutical - Eli Lilly - Emisphere Technologies - Faust Pharmaceuticals - GlaxoSmithKline - Hanmi Pharmaceuticals - Ipse - Mannkind - MDRNA (ex Nastech Pharmaceuticals) - Modigene - Novo Nordisk - OctoPlus - Oramed Pharmaceuticals - Pfizer - Proxima Concepts - Roche (& Chugai) - Rose Pharmaceuticals (ex Gastrotech) - Sanofi-Aventis - Teijin - Transition Therapeutics - TransTech Pharma - Unigene For more information visit http://www.researchandmarkets.com/research/7d4zkt/competitor
Emisphere Technologies, Inc. Announces Financial Results for Quarter Ended June 30, 2014
GlobeNewswire - Thu Aug 14, 7:00AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company" today announced its financial results for the quarter ended June 30, 2014. The Company will host a conference call on Thursday, August 14, at 8:30 AM ET to discuss these results.
Emisphere Technologies, Inc. Announces Second Quarter 2014 Earnings Conference Call
GlobeNewswire - Wed Aug 13, 12:11PM CDT
Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company" announced today that Management will host a conference call to discuss the Company's financial and operational results for the three months ended June 30, 2014 on Thursday, August 14, 2014 at 8:30 AM ET. A press release will be issued prior to market opening.
Emisphere Technologies, Inc. Announces Financial Results for Fourth Quarter and Year Ended December 31, 2013
GlobeNewswire - Mon Mar 31, 7:13AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company" today announced its financial results for the fourth quarter and year ended December 31, 2013. The Company will host a conference call this morning at 8:30 AM ET to discuss these results.
Emisphere Technologies, Inc. Announces 2013 Earnings Conference Call
GlobeNewswire - Fri Mar 28, 2:01PM CDT
Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company" announced today that Management will host a conference call to discuss the Company's financial and operational results for the twelve months ended December 31, 2013 on Monday, March 31, 2014 at 8:30 AM ET. A press release will be issued prior to market open.
Echo Therapeutics names Michael M. Goldberg to board
M2 - Mon Mar 03, 6:33AM CST
Us-based medical device company Echo Therapeutics Inc (Nasdaq:ECTE) announced on Friday the appointment of Michael M Goldberg, MD, to the company's board of directors.
Worldwide Oral Proteins and Peptides Market Report 2014 - Forecasts to 2024
M2 - Fri Feb 07, 8:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/5fdknx/oral_proteins_and) has announced the addition of the "Worldwide Oral Proteins and Peptides Market Report 2014 - Forecasts to 2024" report to their offering. The 'Oral Proteins and Peptides Market, 2014-2024' report provides a comprehensive analysis of the current state of the market and the likely future evolution over the next ten years. Endogenous peptides are a smart way to utilise body's own resources to design drugs that are more specific and carry great potential to cure hard-to-treat diseases. The protein and peptide therapeutics market is a multi-billion dollar market and researchers are trying their best to improve the therapy by devising strategies for their oral delivery. The report portrays the efforts of various pharmaceutical companies in making the transition towards oral delivery by developing innovative technologies and testing multiple drug candidates based on these technologies. A vast amount of activity is happening in this area as seen by the myriad of discoveries, patents, collaborations and grants. One of the key objectives of this report is to understand the current and future state of the oral proteins and peptide drugs market. This is done by analyzing the following: - Drugs currently available in the market and those under development. - Development and likely sales potential of key marketed and pipeline oral proteins and peptides. - Emerging technologies and key developments supporting the development of improved oral peptide delivery. Key Topics Covered: 1. Executive Summary 1.1. Scope Of The Report 1.2. Research Methodology 1.3. Chapter Outlines 1.4. Key Highlights 1.4.1. Oral Protein And Peptide Market Gained Momentum By The Launch Of Linzess In 2012 1.4.2. Diabetes Dominates The Market 1.4.3. Around 40% Of Molecules Are In The Second Or Higher Phase Of Clinical Development 1.4.4. Sandimmune And Ddavp: Two Oral Peptides Available For More Than A Decade 1.4.5. Gipet And Axcess Are The Most Prominent Technologies 2. Introduction 2.1. Chapter Overview 2.2. Comparison Of Protein / Peptide Drugs With Small Molecule Drugs 2.3. Route Of Administration 2.4. Development Challenges 2.5. Oral Proteins And Peptides 3. Overview And Market Background 4. Drug Profiles And Market Forecast 4.1. Introduction 4.2. Overall Market 4.3. Linaclotide (Linzess / Constella) 4.4. In-105 4.5. Ostora 4.6. Octreolin 4.7. Plecanatide 5. Case Studies: Liprotamase, Sandimmune, Ddavp 5.1. Liprotamase 5.2. Sandimmune 5.3. Ddavp / Minirin (Desmopressin) 6. Technology Platforms 6.1. Chapter Overview 6.2. Gastrointestinal Permeation Enhancement Technology, Gipet (Merrion Pharmaceuticals) 6.3. Eligen (Emisphere Technologies) 6.4. Peptelligence (Enteris Biopharma) 6.5. Oral Antibody Platform (Avaxia Biologics) 6.6. Axcess (Proxima Concepts) 6.7. Multi Matrix System (Cosmo Pharmaceuticals) 6.8. Oramed Pod (Protein Oral Delivery) Technology 7. SWOT Analysis 7.1. Strengths 7.2. Weaknesses 7.3. Opportunities 7.4. Threats 8. Conclusion 8.1. The Rise Of New Technologies 8.2. The Preferred Delivery Mode For A Host Of Indications 8.3. An Emerging Market Close To The Tipping Point 8.4. Challenges Exist, Though These Can Be Surpassed 9. Appendix 1: Tables 10. Appendix 2: List Of Companies For more information visit http://www.researchandmarkets.com/research/5f...oteins_and
OTC Signal Daily Stock Watch - Emisphere Technologies, Inc., (OTC: EMIS)
WorldStockWire - Wed Sep 11, 11:00PM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Avitaminosis (Hypovitaminosis) - Pipeline Review, H2 2012
M2 - Wed Jul 31, 4:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9m8vpx/avitaminosis) has announced the addition of the "Avitaminosis (Hypovitaminosis) - Pipeline Review, H2 2012" report to their offering. This report provides an overview of the indication's therapeutic pipeline. It provides information on the therapeutic development for Avitaminosis (Hypovitaminosis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Avitaminosis (Hypovitaminosis). The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Avitaminosis (Hypovitaminosis). - A review of the Avitaminosis (Hypovitaminosis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Avitaminosis (Hypovitaminosis) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Avitaminosis (Hypovitaminosis) Overview Therapeutics Development An Overview of Pipeline Products for Avitaminosis (Hypovitaminosis) Companies Involved in Avitaminosis (Hypovitaminosis) Therapeutics Development Kyowa Hakko Kirin Co Zeria Pharmaceutical Co Emisphere Technologies Cytochroma Inc Avitaminosis (Hypovitaminosis) - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Route of Administration Assessment by Molecule Type Drug Profiles with Product Descriptions and Mechanisms of Action Featured News & Press Releases Appendix For more information visit http://www.researchandmarkets.com/research/9m...itaminosis
Emisphere Technologies, Inc. Announces Financial Results for Quarter Ended March 31, 2013
GlobeNewswire - Wed May 15, 7:00AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company" today announced its financial results for the quarter ended March 31, 2013. The Company will host a conference call this morning at 8:30 AM ET to discuss these results.
Emisphere Technologies, Inc. Announces First Quarter 2013 Earnings Conference Call
GlobeNewswire - Mon May 13, 5:04PM CDT
Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company" announced today that management will host a conference call to discuss the Company's financial and operational results for the first quarter ended March 31, 2013 on Wednesday, May 15, 2013 at 8:30 AM ET. A press release will be issued prior to market open.
Novo Nordisk and EMIS Modify Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 01, 3:18PM CDT
Novo Nordisk and Emispher recently modified their agreement for the development and commercialization of oral formulations of Novo Nordisk's proprietary GLP-1 receptor against candidates.
Emisphere Technologies Inc amends Oral GLP-1 Development License Agreement with Novo Nordisk
M2 - Tue Apr 30, 7:39AM CDT
Biopharmaceutical company Emisphere Technologies Inc (OTC BB:EMIS) said on Monday that it has agreed to amend the Development and License Agreement with Novo Nordisk A/S (NYSE:NVO) for the oral formulations of Novo Nordisk's proprietary GLP-1 receptor agonists for the potential treatment of Type 2 diabetes using Emisphere's Eligen technology.
Emisphere Announces Restructuring of MHR Obligations
GlobeNewswire - Mon Apr 29, 7:31AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company" today announced that it has reached agreement with MHR Fund Management LLC and its various affiliated funds (collectively "MHR" to restructure the terms of its obligations under various promissory notes issued to MHR.
Emisphere Announces Amendment to Oral GLP-1 Development License Agreement With Novo Nordisk
GlobeNewswire - Mon Apr 29, 7:30AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) today announced that it has agreed with Novo Nordisk A/S (NYSE:NVO) to amend the two companies' Development and License Agreement to develop and commercialize oral formulations of Novo Nordisk's proprietary GLP-1 receptor agonists, which have the potential of treating Type 2 diabetes, using Emisphere's Eligentechnology (the "Oral GLP-1 Development Agreement" .
Genital Herpes - Pipeline Review, H1 2013
M2 - Thu Apr 04, 6:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pfc5q6/genital_herpes) has announced the addition of the "Genital Herpes - Pipeline Review, H1 2013" report to their offering. 'Genital Herpes - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Genital Herpes, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Genital Herpes. Scope - A snapshot of the global therapeutic scenario for Genital Herpes. - A review of the Genital Herpes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
Emisphere enters into USD20m debt financing to introduce oral Eligen B12 in the US market
M2 - Thu Aug 21, 7:31AM CDT
Pharmaceutical company Emisphere Technologies (OTC BB:EMIS) reported on Wednesday the execution of new loan facility agreement to finance the upcoming launch of its first commercial prescription product oral Eligen B12 in the US for B12 deficient individuals.
Emisphere Announces $20 Million Debt Financing to Launch Oral Eligen(R) B12
GlobeNewswire - Wed Aug 20, 8:29AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company"
today announced that it has reached agreement with MHR Fund Management LLC, and certain of its affiliated funds ("MHR" , to finance the upcoming launch of the Company's first commercial prescription product, oral Eligen B12 in the United States through a new loan facility, and to amend the terms of the Company's existing obligations under various promissory notes previously issued to MHR to extend the maturity dates of such promissory notes. Competitor Analysis: GLP-1 Receptor Agonists Development Pipeline Report 2014
M2 - Tue Aug 19, 9:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7d4zkt/competitor) has announced the addition of the "Competitor Analysis: GLP-1 Receptor Agonists" report to their offering. The Competitive Intelligence Report Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists as of August 2014 provides a competitor analysis in the development pipeline of novel GLP-1 analogs and GLP-1 receptor agonists and co-agonists for treatment of diabetes and obesity. In the year 2013, the marketed daily and weekly GLP-1 agonists achieved combined sales of US$ 3,231 mln representing 6.3% of the total diabetes care market. The leading GLP-1 analog Victoza held 69% of the GLP-1 market and is further expanding its predominance in the first half of 2014 with a 72% share of the GLP-1 market which grew to 6.9% of the total diabetes care market. The increasingly attractive GLP-1 market provides an opportunity of application of new technologies to prolong the half-life of GLP-1 analogs as well as finding co-agonists of GLP-1 receptor with additional receptors, such as insulin, glucagon, GIP, gastrin or GLP-1. In addition, expansion of indications for GLP-1 analogs will contribute to further expand the GLP-1 market. The report provides a compilation of current active projects in research and development of novel GLP-1 analogs and GLP-1 receptor agonists as well as co-agonists. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage - Additional comments with a hyperlink leading to the source of information. Key Topics Covered: 1. Selective GLP-1 Analogs for Metabolic Diseases - 2013 Sales of GLP-1 Analogs - Short-Acting Injectable GLP-1 Analogs - Long-Acting Injectable GLP-1 Analogs - Very Long-Acting Injectable GLP-1 Analogs - Oral Peptide-Based GLP-1 Analogs - Other Non-Injectable Peptide-Based GLP-1 Analogs - Oral Small Molecule GLP-1 Receptor Agonists 2. Selective GLP-1 Analogs for Non-Metabolic Diseases 3. Dual Target GLP-1 Analogs - GLP-1 and Insulin - GLP-1 and Glucagon - GLP-1 and GIP - GLP-1 and Gastrin/CCKB - GLP-1 and GLP-2 4. Corporate GLP-1 Receptor Agonist R&D Pipelines Companies Mentioned - Addex Pharmaceuticals - Amylin Pharmaceuticals - Arisaph Pharmaceuticals - Arisgen - Ascendis Pharma (Complex Biosystems) - Bio-ker - Biocompatibles International - ConjuChem - Dong-A Pharmaceutical - Eli Lilly - Emisphere Technologies - Faust Pharmaceuticals - GlaxoSmithKline - Hanmi Pharmaceuticals - Ipse - Mannkind - MDRNA (ex Nastech Pharmaceuticals) - Modigene - Novo Nordisk - OctoPlus - Oramed Pharmaceuticals - Pfizer - Proxima Concepts - Roche (& Chugai) - Rose Pharmaceuticals (ex Gastrotech) - Sanofi-Aventis - Teijin - Transition Therapeutics - TransTech Pharma - Unigene For more information visit http://www.researchandmarkets.com/research/7d4zkt/competitor
Emisphere Technologies, Inc. Announces Financial Results for Quarter Ended June 30, 2014
GlobeNewswire - Thu Aug 14, 7:00AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company"
today announced its financial results for the quarter ended June 30, 2014. The Company will host a conference call on Thursday, August 14, at 8:30 AM ET to discuss these results. Emisphere Technologies, Inc. Announces Second Quarter 2014 Earnings Conference Call
GlobeNewswire - Wed Aug 13, 12:11PM CDT
Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company"
announced today that Management will host a conference call to discuss the Company's financial and operational results for the three months ended June 30, 2014 on Thursday, August 14, 2014 at 8:30 AM ET. A press release will be issued prior to market opening. Emisphere Technologies, Inc. Announces Financial Results for Fourth Quarter and Year Ended December 31, 2013
GlobeNewswire - Mon Mar 31, 7:13AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company"
today announced its financial results for the fourth quarter and year ended December 31, 2013. The Company will host a conference call this morning at 8:30 AM ET to discuss these results. Emisphere Technologies, Inc. Announces 2013 Earnings Conference Call
GlobeNewswire - Fri Mar 28, 2:01PM CDT
Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company"
announced today that Management will host a conference call to discuss the Company's financial and operational results for the twelve months ended December 31, 2013 on Monday, March 31, 2014 at 8:30 AM ET. A press release will be issued prior to market open. Echo Therapeutics names Michael M. Goldberg to board
M2 - Mon Mar 03, 6:33AM CST
Us-based medical device company Echo Therapeutics Inc (Nasdaq:ECTE) announced on Friday the appointment of Michael M Goldberg, MD, to the company's board of directors.
Worldwide Oral Proteins and Peptides Market Report 2014 - Forecasts to 2024
M2 - Fri Feb 07, 8:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/5fdknx/oral_proteins_and) has announced the addition of the "Worldwide Oral Proteins and Peptides Market Report 2014 - Forecasts to 2024" report to their offering. The 'Oral Proteins and Peptides Market, 2014-2024' report provides a comprehensive analysis of the current state of the market and the likely future evolution over the next ten years. Endogenous peptides are a smart way to utilise body's own resources to design drugs that are more specific and carry great potential to cure hard-to-treat diseases. The protein and peptide therapeutics market is a multi-billion dollar market and researchers are trying their best to improve the therapy by devising strategies for their oral delivery. The report portrays the efforts of various pharmaceutical companies in making the transition towards oral delivery by developing innovative technologies and testing multiple drug candidates based on these technologies. A vast amount of activity is happening in this area as seen by the myriad of discoveries, patents, collaborations and grants. One of the key objectives of this report is to understand the current and future state of the oral proteins and peptide drugs market. This is done by analyzing the following: - Drugs currently available in the market and those under development. - Development and likely sales potential of key marketed and pipeline oral proteins and peptides. - Emerging technologies and key developments supporting the development of improved oral peptide delivery. Key Topics Covered: 1. Executive Summary 1.1. Scope Of The Report 1.2. Research Methodology 1.3. Chapter Outlines 1.4. Key Highlights 1.4.1. Oral Protein And Peptide Market Gained Momentum By The Launch Of Linzess In 2012 1.4.2. Diabetes Dominates The Market 1.4.3. Around 40% Of Molecules Are In The Second Or Higher Phase Of Clinical Development 1.4.4. Sandimmune And Ddavp: Two Oral Peptides Available For More Than A Decade 1.4.5. Gipet And Axcess Are The Most Prominent Technologies 2. Introduction 2.1. Chapter Overview 2.2. Comparison Of Protein / Peptide Drugs With Small Molecule Drugs 2.3. Route Of Administration 2.4. Development Challenges 2.5. Oral Proteins And Peptides 3. Overview And Market Background 4. Drug Profiles And Market Forecast 4.1. Introduction 4.2. Overall Market 4.3. Linaclotide (Linzess / Constella) 4.4. In-105 4.5. Ostora 4.6. Octreolin 4.7. Plecanatide 5. Case Studies: Liprotamase, Sandimmune, Ddavp 5.1. Liprotamase 5.2. Sandimmune 5.3. Ddavp / Minirin (Desmopressin) 6. Technology Platforms 6.1. Chapter Overview 6.2. Gastrointestinal Permeation Enhancement Technology, Gipet (Merrion Pharmaceuticals) 6.3. Eligen (Emisphere Technologies) 6.4. Peptelligence (Enteris Biopharma) 6.5. Oral Antibody Platform (Avaxia Biologics) 6.6. Axcess (Proxima Concepts) 6.7. Multi Matrix System (Cosmo Pharmaceuticals) 6.8. Oramed Pod (Protein Oral Delivery) Technology 7. SWOT Analysis 7.1. Strengths 7.2. Weaknesses 7.3. Opportunities 7.4. Threats 8. Conclusion 8.1. The Rise Of New Technologies 8.2. The Preferred Delivery Mode For A Host Of Indications 8.3. An Emerging Market Close To The Tipping Point 8.4. Challenges Exist, Though These Can Be Surpassed 9. Appendix 1: Tables 10. Appendix 2: List Of Companies For more information visit http://www.researchandmarkets.com/research/5f...oteins_and
OTC Signal Daily Stock Watch - Emisphere Technologies, Inc., (OTC: EMIS)
WorldStockWire - Wed Sep 11, 11:00PM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Avitaminosis (Hypovitaminosis) - Pipeline Review, H2 2012
M2 - Wed Jul 31, 4:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9m8vpx/avitaminosis) has announced the addition of the "Avitaminosis (Hypovitaminosis) - Pipeline Review, H2 2012" report to their offering. This report provides an overview of the indication's therapeutic pipeline. It provides information on the therapeutic development for Avitaminosis (Hypovitaminosis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Avitaminosis (Hypovitaminosis). The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Avitaminosis (Hypovitaminosis). - A review of the Avitaminosis (Hypovitaminosis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Avitaminosis (Hypovitaminosis) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Avitaminosis (Hypovitaminosis) Overview Therapeutics Development An Overview of Pipeline Products for Avitaminosis (Hypovitaminosis) Companies Involved in Avitaminosis (Hypovitaminosis) Therapeutics Development Kyowa Hakko Kirin Co Zeria Pharmaceutical Co Emisphere Technologies Cytochroma Inc Avitaminosis (Hypovitaminosis) - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Route of Administration Assessment by Molecule Type Drug Profiles with Product Descriptions and Mechanisms of Action Featured News & Press Releases Appendix For more information visit http://www.researchandmarkets.com/research/9m...itaminosis
Emisphere Technologies, Inc. Announces Financial Results for Quarter Ended March 31, 2013
GlobeNewswire - Wed May 15, 7:00AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company"
today announced its financial results for the quarter ended March 31, 2013. The Company will host a conference call this morning at 8:30 AM ET to discuss these results. Emisphere Technologies, Inc. Announces First Quarter 2013 Earnings Conference Call
GlobeNewswire - Mon May 13, 5:04PM CDT
Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company"
announced today that management will host a conference call to discuss the Company's financial and operational results for the first quarter ended March 31, 2013 on Wednesday, May 15, 2013 at 8:30 AM ET. A press release will be issued prior to market open. Novo Nordisk and EMIS Modify Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 01, 3:18PM CDT
Novo Nordisk and Emispher recently modified their agreement for the development and commercialization of oral formulations of Novo Nordisk's proprietary GLP-1 receptor against candidates.
Emisphere Technologies Inc amends Oral GLP-1 Development License Agreement with Novo Nordisk
M2 - Tue Apr 30, 7:39AM CDT
Biopharmaceutical company Emisphere Technologies Inc (OTC BB:EMIS) said on Monday that it has agreed to amend the Development and License Agreement with Novo Nordisk A/S (NYSE:NVO) for the oral formulations of Novo Nordisk's proprietary GLP-1 receptor agonists for the potential treatment of Type 2 diabetes using Emisphere's Eligen technology.
Emisphere Announces Restructuring of MHR Obligations
GlobeNewswire - Mon Apr 29, 7:31AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company"
today announced that it has reached agreement with MHR Fund Management LLC and its various affiliated funds (collectively "MHR" to restructure the terms of its obligations under various promissory notes issued to MHR. Emisphere Announces Amendment to Oral GLP-1 Development License Agreement With Novo Nordisk
GlobeNewswire - Mon Apr 29, 7:30AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) today announced that it has agreed with Novo Nordisk A/S (NYSE:NVO) to amend the two companies' Development and License Agreement to develop and commercialize oral formulations of Novo Nordisk's proprietary GLP-1 receptor agonists, which have the potential of treating Type 2 diabetes, using Emisphere's Eligentechnology (the "Oral GLP-1 Development Agreement"
. Genital Herpes - Pipeline Review, H1 2013
M2 - Thu Apr 04, 6:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pfc5q6/genital_herpes) has announced the addition of the "Genital Herpes - Pipeline Review, H1 2013" report to their offering. 'Genital Herpes - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Genital Herpes, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Genital Herpes. Scope - A snapshot of the global therapeutic scenario for Genital Herpes. - A review of the Genital Herpes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
